You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
SBC: SignalRx Pharmaceuticals Inc. Topic: 102DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
SBC: SignalRx Pharmaceuticals Inc. Topic: NCIPARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Measuring Bladder Permeability with MRI using a Novel Contrast Agent Formulation
SBC: Lipella Pharmaceuticals Inc. Topic: 400DESCRIPTION provided by applicant This project entails the development of a novel dual component MRI contrast agent formulation for the detecting permeability in the luminal surface of the urinary bladder The purpose of having such a test is ultimately to allow clinicians in certain circumstances to differentially diagnose a chronic non infectious inflammation of the urinary bladder from a ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Mechanistic Studies of a Novel Small Molecule HIV Inhibitor
SBC: ADVANCED GENETIC SYSTEMS, INC. Topic: 100DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance
SBC: EXSCIEN CORPORATION Topic: NIDDKDESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Mobile Phone Intervention for Physical Activity Maintenance in African American Men (MobileMen)
SBC: KLEIN BUENDEL, INC. Topic: NIMHDDESCRIPTION provided by applicant African American men experience health disparities across a number of preventable chronic diseases including cardiovascular disease strokes obesity and diabetes Physical activity PA is a modifiable risk factor for these conditions The few PA promotion studies that have included African American men have resulted in successful short term behavior change ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
SBC: VIROGENICS, INC. Topic: NIAIDDESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
mTOR Substrate Phosphorylation: A New Bioassay for Therapeutics
SBC: COGNIZANCE BIOMARKERS, LLC Topic: 107DESCRIPTION provided by applicant There are a growing number of human diseases that have been linked to abnormally enhanced activation of the mammalian target of rapamycin mTOR signaling cascade a central pathway governing eukaryotic protein synthesis These include neurodevelopmental disorders associated with epilepsy autism and intellectual disability as well as cancer obesity and dia ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Nanoliter electron paramagnetic resonance sensor based on diamond nanophotonics: a new tool for biomarker monitoring
SBC: ODMR Technologies, Inc Topic: 400DESCRIPTION provided by applicant ODMR Technologies Inc together with Victor Acostaandapos s group at University of New Mexico is developing a nanophotonic platform capable of uniquely detecting minute quantities of biomolecules The specific detection of biomolecules plays a central role in modern life science including cell systems biology high throughput drug scre ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Neurotrophic Agents for Treating Parkinson's Disaese
SBC: SENEB BIOSCIENCES INC Topic: 102DESCRIPTION provided by applicant Parkinsonandapos s disease PD is a neurodegenerative disorder characterized by motor function and eventually cognitive decline GM depletion is validated as a therapeutic target for Parkinsonandapos s disease PD in clinical studies in which GM replacement stabilized motor function loss and may be disease modifying However GM has poor pharmacologic prop ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health